Abstract | PURPOSE: Metastatic cancers of unknown primary origin are characterised by a poor prognosis, with a survival rate from diagnosis of approximately 12 months. Conventional radiological imaging allows detection of 20%-27% of primary cancers, whereas the detection rate with positron emission tomography (PET) is 24%-40%. The aim of this study was to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in the identification of occult primary cancers. MATERIALS AND METHODS: The study population consisted of 38 consecutive patients with histologically proven metastatic disease and negative or nonconclusive conventional diagnostic procedures. All patients were studied by 18F-FDG PET performed according to the standard procedure (6 h of fasting, intravenous injection of 370 MBq 18F-FDG, and image acquisition with a PET/CT scanner for 4 min per bed position). RESULTS: 18F-FDG-PET/CT detected the occult primary cancer in 20 cases (53%), showing higher sensitivity than that reported for any other imaging modality, including PET. CONCLUSIONS: The encouraging results, if validated by larger series, support the use of PET/CT in patients with carcinoma of unknown primary origin and negative conventional imaging results.
|
Authors | V Ambrosini, C Nanni, D Rubello, A Moretti, G Battista, P Castellucci, M Farsad, L Rampin, G Fiorentini, R Franchi, R Canini, S Fanti |
Journal | La Radiologia medica
(Radiol Med)
Vol. 111
Issue 8
Pg. 1146-55
(Dec 2006)
ISSN: 0033-8362 [Print] Italy |
PMID | 17171520
(Publication Type: Journal Article)
|
Chemical References |
- Radiopharmaceuticals
- Fluorodeoxyglucose F18
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Carcinoma
(diagnosis, diagnostic imaging, secondary)
- Female
- Fluorodeoxyglucose F18
- Humans
- Male
- Middle Aged
- Neoplasms, Unknown Primary
(diagnosis, diagnostic imaging)
- Positron-Emission Tomography
(methods)
- Prognosis
- Radiopharmaceuticals
- Reproducibility of Results
- Sensitivity and Specificity
- Tomography, X-Ray Computed
|